IXI

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

IXI - overview

Established

2021

Location

Espoo, -, Finland

Primary Industry

Healthcare Specialists

About

Based in Finland, IXI specializes in adaptive eyewear technology that automatically adjusts focus based on user eye movements, providing a tailored vision correction experience for diverse visual tasks. Founded in 2021 in Espoo, Finland, IXI develops innovative eyewear solutions. The founders Klaus Melakari, Rebecca Melakari, and Ville Miettinen, have positioned the company to revolutionize the optical industry. IXI has successfully conducted three funding rounds, with the most recent being a SERIES A round on April 28, 2025, where it raised EUR 32.


2 mn led by Plural UK Management and supported by notable investors including Amazon and Eurazeo. The total amount raised by the company is EUR 32. 2 mn. IXI is pioneering the eyewear industry with its innovative core product, the IXI Adaptive Eyewear, which features lenses that automatically adjust focus based on the user's eye movements.


This technology allows seamless transitions between near and far viewing, catering to individuals requiring dynamic vision correction. The product aims to enhance user experiences by providing an adaptive solution that accommodates various visual tasks, significantly improving daily activities such as reading, driving, or using electronic devices. Currently, IXI Adaptive Eyewear is in development and has not yet been released to the market, with potential reach in developed regions with strong demand for optical solutions, such as North America and Europe. IXI's revenue details for the most recent year, 2022, indicate an amount of EUR 0.


The EBITDA for 2023 is reported as EUR -4,874,155. 40. The company anticipates a direct-to-consumer sales model, likely using online platforms and partnerships with retail eyewear outlets. Revenue generation will likely involve one-time purchases or subscription-based models for lens updates and maintenance, positioning the IXI Adaptive Eyewear at a premium price point due to its advanced technology and design.


In April 2025, IXI raised EUR 32. 2 mn in SERIES A funding, led by Plural UK Management, to complete the development of its autofocus glasses and launch commercial operations. This funding will support the introduction of real-time adaptive eyewear to the market. The company aims for a release of its innovative product in the near future, with plans to expand into markets in North America and Europe, targeting consumers who require advanced optical solutions.


Current Investors

Bragiel Brothers, Firstminute Capital, Maki.vc

Primary Industry

Healthcare Specialists

Sub Industries

Optometrists & Opticians Products and Services, Therapeutic Devices

Website

www.ixieyewear.com

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.